Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.
about
Anti-hepatitis C virus drugs and kidneyHepatitis C Therapy in Renal Patients: Who, How, When?Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney diseaseComparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis.Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience.Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.Hepatitis C Virus Infection in Chronic Kidney Disease.Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Management of Post-Liver Transplant Recurrence of Hepatitis C.Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.Treatment Options in Hepatitis C.Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis.The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia.Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease.Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen.Decreasing Mortality and Disease Severity in Hepatitis C Patients Awaiting Liver Transplantation in the United States.Clinical trials: Treatment of HCV-infected patients with advanced kidney disease.Transplantation of Kidneys from HCV-Positive Donors: How to Best Use a Scarce Resource.Use of sofosbuvir in chronic kidney disease: Is it necessary?Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C.Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction.
P2860
Q28070279-A373C450-EEBC-41A1-808D-479DBB5764B9Q28077130-92E1B642-EB57-41F0-A9CC-E9725FBA4B67Q28077263-B83532AF-9D4F-4D05-9A76-606740F621B0Q31143582-A944C8E0-2FEF-4E49-915C-1B8CFDE6D551Q33440016-754FFC4D-EF0D-4AC1-8D2C-BF25BC429948Q33621619-024E0A3F-4BD3-4412-A603-228596AE3A9BQ33845581-3121B29B-6448-4AC5-8463-EA2D90ABE43FQ36220536-3D5E7C3E-89D8-4E4D-B0B4-A891DB378867Q37555313-4DFF400A-6CA1-4BCE-8F53-EDDD74F41465Q38615384-6B60A513-DABA-4067-8170-65AC9AC74AFFQ38812607-C84DD0FB-E945-4E69-A27A-311D67DDAC84Q38860565-303D397B-1C02-4260-B506-12242C3ACE3DQ38875903-BF68149C-0205-4191-AE02-54FC2D5217E3Q38975165-015631F8-2E1E-4827-B25A-BA946F94E5ADQ39017681-F5EDFA97-4CA6-4C90-B7D9-98602E316B8EQ39067369-494653D5-6FC4-41EB-B5C6-BBB723489484Q39092977-E8C3D817-BFAA-4288-B742-E3F8AA6B9A3CQ39099569-90BB6CF3-95BB-49A5-A3E8-6CD7F2FCE40FQ39112237-DBE3B77B-B7DA-4288-8345-87EB37EF737DQ39455853-70A0AEE8-937A-450E-B4F1-80C52BE1C2ECQ40052523-68C8D724-8884-4102-9C0C-871F71ABA43DQ40089989-A25179C5-18D1-4423-BF3F-22A14E0513DFQ40215846-AF5024C5-28CD-4595-B3D2-003830CC1E7FQ40278746-E19A6ED6-9A01-4C60-BBD8-B6844C69B6AAQ40413390-711A90A0-9978-402A-BED0-57FF41695F54Q40444467-30A155A6-0EC3-49CE-AF56-D42F8FF1C53EQ40476119-992373AC-1023-494D-954D-3B0CD9569218Q40708768-0F34A483-CB27-4757-A160-2DCACBA50D51Q41925546-64B92AC6-D542-486D-A634-0D483974030CQ42370354-EB29E20E-5E3C-43D4-8F03-929658FEA848Q45325791-7AE64798-6BCC-4254-94C8-D95F47A71A81Q47108436-5E76B62E-4EC4-4EE6-AD28-626926275607Q47583932-51087507-4665-4897-ACD7-920F9FCBDCDAQ47695767-B6FFFC9C-87A7-4CE5-8C61-B6615819E1EAQ47777226-04BE9E91-54B3-4F2D-85CB-9DE56624280DQ48096472-50F4F469-EC37-437B-A640-740369DC4E17Q48507049-B228841F-F97A-4ADF-9EEF-96E9AA3E343CQ49200882-729B2F98-858D-4803-B873-0C7E6ADC61A7Q50208930-988650C5-88B2-43A3-9FCE-772CD7341231Q51754955-DA072B26-72FA-444A-89A7-5E49EB200337
P2860
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Safety and efficacy of sofosbu ...... with impaired renal function.
@en
type
label
Safety and efficacy of sofosbu ...... with impaired renal function.
@en
prefLabel
Safety and efficacy of sofosbu ...... with impaired renal function.
@en
P2093
P2860
P356
P1433
P1476
Safety and efficacy of sofosbu ...... s with impaired renal function
@en
P2093
Annmarie Liapakis
David R Nelson
Farrukh M Koraishy
HCV-TARGET
Joseph K Lim
Meghan E Sise
Michael W Fried
Norah A Terrault
Raymond T Chung
Varun Saxena
P2860
P304
P356
10.1111/LIV.13102
P577
2016-02-29T00:00:00Z